Yeast-based therapeutic for chronic hepatitis C infection
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/29
A61K-039/00
A61K-045/00
C12N-001/00
C12N-001/19
C12N-015/09
C12N-015/51
C12P-021/00
출원번호
UP-0618834
(2006-12-31)
등록번호
US-7632511
(2009-12-24)
발명자
/ 주소
Duke, Richard C.
Franzusoff, Alex
Haller, Aurelia
King, Thomas H.
출원인 / 주소
GlobeImmune, Inc.
대리인 / 주소
Sheridan Ross P.C.
인용정보
피인용 횟수 :
21인용 특허 :
37
초록▼
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in co
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.
대표청구항▼
What is claimed is: 1. A method to reduce hepatitis C virus (HCV) infection or at least one symptom resulting from HCV infection in a subject, comprising administering to a subject a composition comprising: a) a yeast vehicle; and b) an HCV NS3-Core fusion protein comprising HCV sequences, wherein
What is claimed is: 1. A method to reduce hepatitis C virus (HCV) infection or at least one symptom resulting from HCV infection in a subject, comprising administering to a subject a composition comprising: a) a yeast vehicle; and b) an HCV NS3-Core fusion protein comprising HCV sequences, wherein the HCV sequences consist of: i) an HCV NS3 protease sequence consisting of the 262 amino acids of HCV NS3 protease following the initial N-terminal 88 amino acids of full-length HCV NS3 protease (positions 1115 to 1376 with respect to SEQ ID NO:20); and ii) an HCV Core sequence consisting of amino acid positions 2 through 140 of full-length HCV Core sequence (positions 2 to 140, with respect to SEQ ID NO:20); wherein the HCV fusion protein is expressed by the yeast vehicle; wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response; and wherein administration of the composition to the subject reduces HCV infection or at least one symptom resulting from HCV infection in a subject. 2. The method of claim 1, wherein administration of the composition to the subject reduces HCV viral load in the subject. 3. The method of claim 1, wherein administration of the composition to the subject reduces liver damage in the subject. 4. The method of claim 1, further comprising administering to the subject at least one biological response modifier. 5. The method of claim 1, further comprising administering to the subject one or more additional compounds useful for treating or ameliorating a symptom of HCV infection. 6. The method of claim 5, further comprising administering to the subject pegylated interferon-α and ribavirin. 7. The method of claim 1, wherein the composition is administered by injection. 8. The method of claim 1, wherein the subject is a non-responder to interferon based therapy. 9. The method of claim 1, wherein the HCV Core sequence has been appended to include glutamate and aspartate. 10. The method of claim 1, wherein the HCV Core sequence has been appended to include the amino acid sequence of G-G-G-H-H-H-H-H-H (SEQ ID NO:10). 11. The method of claim 1, wherein the HCV NS3 protease sequence is linked at its N-terminus to the amino acid sequence of M-A-D-E-A-P (SEQ ID NO:9). 12. The method of claim 1, wherein the expression of the fusion protein is under the control of an inducible promoter. 13. The method of claim 1, wherein the yeast vehicle is a whole yeast. 14. The method of claim 13, wherein the whole yeast is heat-inactivated. 15. The method of claim 14, wherein the whole yeast is from Saccharomyces cerevisiae. 16. The method of claim 1, wherein the yeast vehicle is from Saccharomyces cerevisiae. 17. A method to reduce hepatitis C virus (HCV) infection or at least one symptom resulting from HCV infection in a subject, comprising administering to a subject a composition comprising: a) a yeast vehicle; and b) an HCV fusion protein consisting of SEQ ID NO:2, wherein expression of the HCV fusion protein is under the control of the promoter CUP1; wherein the HCV fusion protein is expressed by the yeast vehicle; and wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response; wherein administration of the composition to the subject reduces HCV infection or at least one symptom resulting from HCV infection in the subject. 18. The method of claim 17, wherein administration of the composition to the subject reduces HCV viral load in the subject. 19. The method of claim 17, wherein administration of the composition to the subject reduces liver damage in the subject. 20. The method of claim 17, further comprising administering to the subject at least one biological response modifier. 21. The method of claim 17, further comprising administering to the subject one or more additional compounds useful for treating or ameliorating a symptom of HCV infection. 22. The method of claim 21, further comprising administering to the subject pegylated interferon-α and ribavirin. 23. The method of claim 17, wherein the composition is administered by injection. 24. The method of claim 17, wherein the subject is a non-responder to interferon based therapy. 25. The method of claim 17, wherein the yeast vehicle is a whole yeast. 26. The method of claim 25, wherein the whole yeast is heat-inactivated. 27. The method of claim 26, wherein the whole yeast is from Saccharomyces cerevisiae. 28. The method of claim 17, wherein the yeast vehicle is from Saccharomyces cerevisiae. 29. A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen, comprising administering to a subject a composition comprising: a) a yeast vehicle; and b) an HCV NS3-Core fusion protein comprising HCV sequences, wherein the HCV sequences consist of: i) an HCV NS3 protease sequence consisting of the 262 amino acids of HCV NS3 protease following the initial N-terminal 88 amino acids of full-length HCV NS3 protease (positions 1115 to 1376 with respect to SEQ ID NO:20); and ii) an HCV Core sequence consisting of amino acid positions 2 through 140 of full-length HCV Core sequence (positions 2 to 140, with respect to SEQ ID NO:20); wherein the HCV fusion protein is expressed by the yeast vehicle; and wherein the composition elicits an HCV NS3-specific, cell-mediated immune response and an HCV Core-specific, cell-mediated immune response. 30. The method of claim 29, wherein the yeast vehicle is a whole, heat-inactivated yeast. 31. The method of claim 29, wherein the yeast vehicle is from Saccharomyces cerevisiae. 32. A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen, comprising administering to a subject a composition comprising: a) a yeast vehicle; and b) an HCV fusion protein consisting of SEQ ID NO:2, wherein expression of the HCV fusion protein is under the control of the promoter CUP1; wherein the HCV fusion protein is expressed by the yeast vehicle; and wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response. 33. The method of claim 32, wherein the yeast vehicle is a whole, heat-inactivated yeast. 34. The method of claim 32, wherein the yeast vehicle is from Saccharomyces cerevisiae. 35. A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen in a population of individuals who have been infected with HCV, comprising administering to said population of individuals a composition comprising: a) a yeast vehicle; and b) an HCV NS3-Core fusion protein comprising HCV sequences, wherein the HCV sequences consist of: i) an HCV NS3 protease sequence consisting of the 262 amino acids of HCV NS3 protease following the initial N-terminal 88 amino acids of full-length HCV NS3 protease (positions 1115 to 1376 with respect to SEQ ID NO:20); and ii) an HCV Core sequence consisting of amino acid positions 2 through 140 of full-length HCV Core sequence (positions 2 to 140, with respect to SEQ ID NO:20); wherein the HCV fusion protein is expressed by the yeast vehicle; and wherein the composition elicits an HCV NS3-specific, cell-mediated immune response and an HCV Core-specific, cell-mediated immune response. 36. The method of claim 35, wherein the yeast vehicle is a whole, heat-inactivated yeast. 37. The method of claim 36, wherein the whole yeast is from Saccharomyces cerevisiae. 38. A method to elicit an antigen-specific, cell-mediated immune response against an HCV antigen in a population of individuals who have been infected with HCV, comprising administering to said population of individuals a composition comprising: a) a yeast vehicle; and b) an HCV fusion protein consisting of SEQ ID NO:2, wherein expression of the HCV fusion protein is under the control of the promoter CUP1; wherein the HCV fusion protein is expressed by the yeast vehicle; and wherein the composition elicits an HCV NS3-specific, cell-mediated immune response and an HCV Core-specific, cell-mediated immune response. 39. The method of claim 38, wherein the yeast vehicle is a whole, heat-inactivated yeast. 40. The method of claim 39, wherein the whole yeast is from Saccharomyces cerevisiae. 41. A method to reduce hepatitis C virus (HCV) infection or at least one symptom resulting from HCV infection in a subject, comprising administering to a subject a composition comprising: a) a yeast vehicle; and b) an HCV fusion protein consisting of SEQ ID NO:2; wherein the HCV fusion protein is expressed by the yeast vehicle; wherein the composition elicits an HCV NS3-specific immune response and an HCV Core-specific immune response; and wherein administration of the composition to the subject reduces HCV infection or at least one symptom resulting from HCV infection in the subject. 42. The method of claim 41, wherein the yeast vehicle is a whole, heat-inactivated yeast. 43. The method of claim 42, wherein the whole yeast is from Saccharomyces cerevisiae.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (37)
Paliard, Xavier; Houghton, Michael; Selby, Mark, Activation of HCV-specific T cells.
Houghton Michael (Danville CA) Choo Qui-Lim (El Cerrito CA) Kuo George (San Francisco CA), Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies.
Apelian, David; Franzusoff, Alex; Rodell, Timothy C., Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Apelian, David; King, Thomas H.; Guo, Zhimin; Coeshott, Claire, Compositions and methods for the treatment or prevention of hepatitis B virus infection.
Selitrennikoff, Claude P.; Miller, Tamara K., Compositions and methods to elicit immune responses against pathogenic organisms using yeast based vaccines.
Selitrennikoff, Claude P.; Miller, Tamara K, Compositions and methods to elicit immune responses against pathogenic organisms using yeast-based vaccines.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.